Targeting fatty acid metabolism in cancer and endothelial cells

Crit Rev Oncol Hematol. 2016 Jan:97:15-21. doi: 10.1016/j.critrevonc.2015.10.011. Epub 2015 Nov 1.

Abstract

Tumour angiogenesis has long been recognised as a target for anti-cancer therapy. The current approach of inhibiting the VEGF pathway has shown benefit in the clinic, though less than anticipated. We recently documented that glycolytic metabolism in endothelial cells (ECs) fuels angiogenesis, rendering it a possible target for inhibiting vascular growth in pathological conditions. More recently, we reported that the oxidation of fatty acids (FA) is irreplaceable for EC proliferation by providing carbons for de novo nucleotide synthesis. Furthermore, ECs are rather unique in this respect, creating novel therapeutic opportunities. Here, we review and compare the current understanding of FA utilisation in ECs and tumour cells (TCs).

Keywords: Angiogenesis; CPT1A; Cancer cell metabolism; Endothelial cell metabolism; Fatty acid metabolism.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Fatty Acids / metabolism*
  • Glycolysis / drug effects
  • Glycolysis / physiology
  • Humans
  • Lipid Metabolism / drug effects
  • Molecular Targeted Therapy* / methods
  • Molecular Targeted Therapy* / trends
  • Neoplasms / blood supply
  • Neoplasms / metabolism*
  • Neoplasms / therapy*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism

Substances

  • Angiogenesis Inhibitors
  • Fatty Acids